Equities

Vytrus Biotech SA

Vytrus Biotech SA

Actions
  • Price (EUR)2.60
  • Today's Change0.02 / 0.78%
  • Shares traded15.20k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 19 2024 15:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vytrus Biotech SA, formerly Phyture Biotech SL, is Spain-based company principally engaged in the biotechnology industry. The Company develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The Company obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics. Vytrus Biotech specifically target dermo-cosmetics as well as veterinary medicine, functional food and other pharmaceuticals, generating savings of more than 99% in natural resources.

  • Revenue in EUR (TTM)3.74m
  • Net income in EUR544.95k
  • Incorporated2009
  • Employees36.00
  • Location
    Vytrus Biotech SASant Gaieta 121, 2ndTERRASSA 08221SpainESP
  • Phone+34 931278106
  • Websitehttp://www.vytrus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tempest Security AB41.11m299.32k17.01m516.0056.832.4111.510.41380.33520.335246.047.901.98--8.33953,790.501.94-1.224.26-2.85----0.9782-0.60180.72983.800.3217--10.6116.17-62.57---2.90--
Hifab Group AB27.41m1.60m17.07m187.0010.972.796.560.62270.30820.30825.291.211.93--6.30--11.23-1.2424.37-2.97----5.83-0.60590.90528.640.3109--4.22-5.13334.676.5612.04--
Orege SA1.26m-10.19m17.46m30.00------13.87-0.2017-0.20170.0249-0.79550.1251--0.899941,966.67-101.25-79.01-151.13-122.82-----809.13-388.740.921-3.507.07---63.70-11.04-64.09--31.02--
Catenon SA11.54m-177.33k18.17m115.00--7.1944.731.57-0.0098-0.00980.63530.13482.03--3.76100,343.00-3.111.07-5.301.85103.56101.91-1.540.6619--0.32680.3827--7.147.42-113.18--19.57--
Giglio Group SpA17.96m-3.95m18.77m43.00--13.63--1.05-0.1162-0.11620.74310.05220.593420.252.73417,581.40-13.06-8.76-49.80-36.56-10.0913.14-22.01-10.540.3765-5.990.8931---50.93-14.35-89.89---7.06--
React Group PLC24.69m264.38k19.29m296.0083.151.878.030.78120.00910.00910.85480.40421.392,172.144.6570,364.871.49-0.71082.23-1.1127.0027.261.07-0.53081.163.440.0873--43.2442.82107.13--25.65--
RTC Group plc117.11m2.19m19.50m196.008.862.085.640.16650.12700.12706.810.54154.665,609.456.24503,984.708.693.4219.037.7517.6615.471.870.83191.5815.080.249539.5737.372.38625.645.08-2.817.39
Euroconsultants SA5.07m2.06m19.61m40.009.413.819.063.870.13820.13820.34070.34090.5009--2.09126,780.0020.6713.0826.8123.1245.5234.1341.2724.47----0.1676--7.3315.2329.74---9.12--
Vytrus Biotech SA3.74m544.95k19.70m36.0031.963.2815.515.270.08070.08070.55480.78570.43161.236.65103,803.906.295.247.245.9383.6288.3114.5813.261.902.960.282--1.4833.30-9.97------
PION Group AB163.30m-316.52k20.28m2.14k--1.496.600.1242-0.0921-0.092140.284.272.92--4.22595,392.30-0.47295.46-1.2915.44-----0.1621.74----0.142853.70-3.160.7865-124.26---7.650.00
11 88 0 Solutions AG56.60m-3.51m21.90m487.00--7.3312.830.387-0.1525-0.15252.570.11392.43--8.71110,120.60-15.09-9.42-35.03-18.3741.4042.31-6.20-4.70---6.780.5655--1.855.86-23.00---28.73--
HomeMaid AB (publ)38.93m1.19m21.91m908.0020.925.727.610.56290.73630.736324.112.692.0999.7513.92503,306.206.739.5116.3625.4686.1085.923.223.810.77967.070.557578.407.3211.94-40.57-40.98-21.3320.11
Arcario AB22.52m-5.05m22.56m12.00--8.23--1.00-0.0056-0.00560.0270.00263.35--67.8022,036,170.00-75.14-103.82-109.21-139.507.05---22.41-49.04---20.130.00---46.3580.564.46------
Empresaria Group plc296.75m-3.44m22.76m3.15k--0.52732.910.0767-0.0783-0.07835.030.73022.11--6.3279,460.32-1.100.5837-2.631.4222.9722.46-0.51940.2672--2.440.4479---4.21-7.36-185.29---1.37-12.94
Frontier IP Group Plc441.03k-2.40m22.77m21.00--0.4062--51.64-0.0371-0.03710.00660.84190.0076--0.300717,714.29-4.1514.23-4.1814.32-----544.3596.14----0.000.0013.07-30.91-131.71--17.98--
Directa Plus PLC10.53m-3.86m22.89m191.00--2.65--2.17-0.0492-0.04920.13450.06970.72325.592.47---29.36-23.29-44.31-32.5046.8452.09-40.60-53.531.76-34.190.2879---3.0033.3020.03--8.15--
Data as of Jul 19 2024. Currency figures normalised to Vytrus Biotech SA's reporting currency: Euro EUR

Institutional shareholders

0.07%Per cent of shares held by top holders
HolderShares% Held
Renta 4 Gestora SGIIC SAas of 31 Dec 20234.81k0.07%
Data from 29 Mar 2024 - 29 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.